The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer (Q39880884)

15 September 2017

title

The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer (English)

1 reference

15 September 2017

Michael L Eisenberg

1

1 reference

15 September 2017

Janet E Cowan

2

1 reference

15 September 2017

Benjamin J Davies

3

1 reference

15 September 2017

Peter R Carroll

4

1 reference

15 September 2017

Katsuto Shinohara

5

1 reference

15 September 2017

publication date

11 April 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

29

1 reference

15 September 2017

issue

2

1 reference

15 September 2017

page(s)

171-176

1 reference

15 September 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Prostate-specific antigen detected prostate cancer: pathological characteristics of ultrasound visible versus ultrasound invisible tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

The changing face of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Are prostate carcinoma clinical stages T1c and T2 similar?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Is transrectal ultrasonography needed to rule out prostatic cancer with normal findings at digital rectal examination and normal serum prostate-specific antigen?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Active surveillance for the management of prostate cancer in a contemporary cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Who is the average patient presenting with prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Percent tumor involvement and risk of biochemical progression after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

Adenocarcinoma of the prostate: results of routine urological screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

inferred from DOI database lookup

7 January 2021

based on heuristic

The role of transrectal ultrasonography on the palpable and impalpable abnormal prostate

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.01.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2009.01.005

1 reference

15 September 2017

1 reference